cancer patients
Conditions
Interventions
Assign patients to either kestose plus B. longum (synbiotics)
administration group or non-administration group.
Sponsors
Hirooka Yoshiki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who have received sufficient explanation before participating in this study, and have obtained written consent by their own free will with sufficient understanding. 2. Patients aged 20 at the time of consent. 3. Patients who have been receiving chemotherapy.
Exclusion criteria
Exclusion criteria: Patients who are judged to be inappropriate by the investigator and the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the intestinal microbiota and the Bristol stool scale | — |
Secondary
| Measure | Time frame |
|---|---|
| : Determining overall response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) according to Response Evaluation Criteria (RECIST 1.1). : Improvement of nutrition state (body weight, muscle mass, body cell mass, phase angle, serum albumin) : Evaluating nutrition state using Visual Analogue Scale (VAS) : Assessing performance status : Evaluating adverse events using CTCAE v5.0 : Characterizing overall survival (OS) : Assessing Liver function Child-Pugh (CP) score and the Albumin-Bilirubin (ALBI) Grade | — |
Contacts
Public ContactKohei Funasaka
Fujita Health University Hospital
Outcome results
None listed